Latest Conference Coverage

Ubrogepant Demonstrates Several Positive Real-World Migraine Impacts in Patients With Prior Treatment Failure

Following the switch to ubrogepant, more than half of patients with migraine had reduced use of triptans and more than one-third of patients had reduced use of anti-inflammatory drugs.

The Therapeutic Advances in Efficacy for NMOSD: Bruce Cree, MD, PhD, MAS, FAAN

The clinical research director of the UCSF Multiple Sclerosis Center offer his perspective on the 3 available agents for the treatment of patients with neuromyelitis optica spectrum disorder. [WATCH TIME: 2 minutes]

Understanding the Relationship Between Cerebral Arterial Blood Flow and Serum Neurofilament Light in MS

Dejan Jakimovski, MD, PhD, research assistant professor, Buffalo Neuroimaging Analysis Center, discussed his presentation at AAN 2022 on the associations between cerebral hypoperfusion and increased axonal pathology in MS.

Comparing Neurological Examinations of COVID-19 With Other Viral Infections: Matthew Schindler, MD, PhD

The assistant professor of neurology at the University of Pennsylvania discussed the similarities observed between the results of neurological exams in patients with COVID-19 vs other respiratory infections. [WATCH TIME: 3 minutes]

Improving Care for Adults With Intellectual and Developmental Disabilities

Seth M. Keller, MD, chair of the Section for Adults With IDDs at AAN, shared his perspective on the state of care for these individuals and the need to improve the difficulties they face when transitioning out of pediatric care.

SB623’s Potential for Traumatic Brain Injury: Peter J. McAllister, MD, FAAN

The medical director and chief medical officer of the New England Center for Neurology and Headache spoke to the phase 2 STEMTRA trial results of the stem cell treatment SB623. [WATCH TIME: 4 minutes]

GammaCore Noninvasive Vagus Nerve Stimulation Demonstrates Safety, Feasibility in Acute Stroke

All patients received 100% of the intended stimulations, with no reported deaths, stimulation site reactions, or any cases of acute coronary syndrome or symptomatic intracerebral hemorrhage.

Patients With Narcolepsy Prefer Once-Nightly FT218 Over Twice-Nightly Sodium Oxybates, Data Suggests

Among those who took their second nighttime sodium oxybate dose 4 hours after their first, 42% claimed they felt somewhat, quite a bit, or extremely groggy or unsteady the next morning.

RISE-PD Study of IPX-203 in Parkinson Disease: Robert A. Hauser, MD, MBA

The director of the Parkinson’s Disease and Movement Disorder Center at the University of South Florida detailed the data presented at AAN 2022 and IPX-203’s potential in Parkinson disease. [WATCH TIME: 3 minutes]

NeuroVoices: Elia Pestana-Knight, MD, on the Importance of Ganaxolone’s Approval in CDD

The pediatric epileptologist at Cleveland Clinic’s Epilepsy Center discussed data presented at AAN 2022 on the use of ganaxolone in CDD, as well as how its recent approval sets the stage for the future.

Satralizumab Eliminates Protocol-Defined Relapse in NMOSD, Long-Term Analysis Demonstrates

Low annualized relapse rates determined by investigator were observed and sustained over a 3.5-year period with treatment of satralizumab.

Overcoming Challenges in Neurology Associated With the COVID-19 Pandemic

In the AAN 2022 presidential plenary session, a trio of neurologists discussed a variety of issues stemming from the COVID-19 pandemic and how they impacted research efforts in neurological diseases.

Combination Agent P2B001 Shows Promise for Parkinson Disease in Phase 3 Data

The Pharma Two B therapy combines a dopamine agonist, pramipexole, and an MAO-B inhibitor, rasagiline, and has shown significant improvements on UPDRS total scores and ESS scores for untreated patients with PD.

24-hour Subcutaneous Foslevodopa/Foscarbidopa Demonstrates Several Benefits for Parkinson Disease

At week 26, patients on ABBV-951 had mean increases of 3.24 hours in ON time and decreases of 2.94 hours of OFF time, which was similar to previously reported studies.

The Quick Neurologic Examination Tool in the PICU: Apirada Thongsing, MD

The resident physician at Montefiore Medical Center shared her experience with the novel and standardized quick examination tool and the data presented at AAN 2022. [WATCH TIME: 3 minutes]

Ocrelizumab Shows Improved Cognition, Low Disease Activity in Progressive MS Interim Data

One-year data from the single-arm phase 3b CONSONANCE trial (NCT03523858) suggest that the Genentech agent (Ocrevus) resulted in low levels of disease activity and improved cognitive performance in those with secondary and primary progressive multiple sclerosis.

Targeting Senescent Cells to Address Alzheimer Disease and Neurodegeneration

In an AAN 2022 Hot Topics plenary session, Miranda E. Orr, PhD, highlighted the potential of targeting senescent cells with senolytics as a therapeutic approach to age-related diseases such as Alzheimer disease, and detailed the ongoing phase 2 SToMP-AD clinical trial (NCT04685590).

Understanding Long-Term Neurological Trajectories in Severe COVID-19 Cases: Jennifer Frontera, MD

The professor of neurology at NYU Langone Grossman School of Medicine discussed her talk at AAN 2022 on neurological sequelae and follow-up in hospitalized and nonhospitalized patients with COVID-19. [WATCH TIME: 8 minutes]

Case Study Attests to Nusinersen’s Safety as a Bridge Therapy to Zolgensma

After switching from nusinersen to Zolgensma 147 days into life, the infant scored a 64 on CHOP-INTEND score, considerably higher than what is observed in the natural history.

Quick Neurologic Examination Feasible, Valid for PICU Neurological Examinations

In an assessment including 23 patients, the novel and standardized quick neurologic examination showed excellent interrater reliability and agreement, suggesting good validity.

Inebilizumab’s Efficacy in Patients With NMOSD Early in Disease Course: Bruce Cree, MD, PhD, MAS, FAAN

The clinical research director of the UCSF Multiple Sclerosis Center discussed new data presented at AAN on inebilizumab (Uplizna; Horizon) in neuromyelitis optica spectrum disorder. [WATCH TIME: 4 minutes]

The Paradigm Shift in Therapeutic Intervention for ALS: Matthew Kiernan, MBBS, PhD, DSc, FRACP, FAHMS

The Bushell Chair of Neurology at the University of Sydney offered his perspective on phase 2 data of CNM-Au8 in amyotrophic lateral sclerosis and spoke to the advances that the field has made in recent years. [WATCH TIME: 3 minutes]

Secondary Data Show Continued Efficacy With Cefaly Trigeminal Nerve Stimulation for Migraine

At 2 hours post-stimulation, 42.5% of those on the Cefaly device had absence of most bothersome symptoms compared with 34.1% of those in the sham group.

Next Steps in Tackling CDKL5 Deficiency Disorder Following First Approval: Elia Pestana-Knight, MD

The pediatric epileptologist from Cleveland Clinic provided commentary on the changes needed to improve research and drug development in CDKL5 deficiency disorder, as well as the organizations committed to advancing the state of care. [WATCH TIME: 3 minutes]

Pepinemab Demonstrates Improved Cognition in Subgroup Analysis in Huntington Disease

On fluorodeoxyglucose PET, pepinemab slowed or reversed decline in metabolic activity in all 26 brain regions observed, with significant benefit found in 15 regions.

SAGE-718 Demonstrates Safety, Signs of Improvement in Phase 2 Alzheimer Disease Study

Sage Therapeutics’ investigational NMDA receptor positive allosteric modulator was well-tolerated, with signs of cognitive and functional improvements reported for patients with AD in the phase 2 LUMINARY study.

AXS-07 Reduces Migraine Pain in Long-Term Phase 3 MOVEMENT Trial

Through both 24 and 48 hours after single-dose treatment, 85% and 83% of patients, respectively, remained free of the need for rescue medication.

Ganaxolone’s Approval Springboards Future CDD Drug Development: Elia Pestana-Knight, MD

The pediatric epileptologist at Cleveland Clinic discussed the impact of ganaxolone’s approval for CDKL5 deficiency disorder and how it may create an opportunity for future pipeline agents. [WATCH TIME: 3 minutes]

CNM-Au8 Shows Survival Benefit for Patients With ALS in Phase 2 Extension

Interim data from the phase 2 RESCUE-ALS trial open-label extension suggest that Clene Nanomedicine’s investigational agent, CNM-AU8, offered benefits to patients with ALS in terms of survival, in addition to prior results suggestive of slowed progression.

CNM-Au8 Data From the RESCUE-ALS Open-Label Extension: Matthew Kiernan, MBBS, PhD, DSc, FRACP, FAHMS

The Bushell Chair of Neurology at the University of Sydney shared his insight into the latest data on CNM-Au8 as a potential treatment for amyotrophic lateral sclerosis and the frameshift in treatment that it represents. [WATCH TIME: 3 minutes]